Yahoo Suche Web Suche

Suchergebnisse

1. Suchergebnisse:

1. de.wikipedia.org › wiki › John_FJohn F. Seymour – Wikipedia

   de.wikipedia.org › wiki › John_F

   • Im Cache

   John F. Seymour (* 3. Dezember 1937 in Chicago, Illinois) ist ein US-amerikanischer Immobilieninvestor und Politiker ( Republikanische Partei ), der den Bundesstaat Kalifornien im US-Senat vertrat.

2. Bilder

   • 
   • 
   • 
   • 
   • 
   • 

   Alle anzeigen

3. en.wikipedia.org › wiki › John_Seymour_(California_politician)John Seymour (California politician) - Wikipedia

   en.wikipedia.org › wiki › John_Seymour_(California_politician)

   • Im Cache

   John Francis Seymour Jr. (born December 3, 1937) is an American retired politician who served as a United States senator from California from 1991 to 1992.

4. www.nejm.org › doi › fullVenetoclax–Rituximab in Relapsed or Refractory Chronic...

   www.nejm.org › doi › full

   21. März 2018 · Anderson MA, Deng J, Seymour JF, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

   • Autor: John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, James D’Rozario, Sarit Assouline...

   • Publish Year: 2018

5. scholar.google.com › citations‪John F Seymour‬ - ‪Google Scholar‬

   scholar.google.com › citations

   • Im Cache

   John F Seymour. Professor of Medicine, Director Dept of Haematology Peter MacCallum Cancer Centre & Royal Melbourne. Verified email at petermac.org - Homepage. Hematologic malignancies....

6. ashpublications.org › blood › articleDegraders upgraded: the rise of PROTACs in hematological...

   ashpublications.org › blood › article

   • Im Cache

   28. März 2024 · Casan and Seymour provide a state-of-the-art review of proteolysis-targeting chimeras (PROTACs), the leading class of targeted protein degradation agents.

7. onlinelibrary.wiley.com › doi › 10Approach to relapsed CLL including Richter Transformation -...

   onlinelibrary.wiley.com › doi › 10

   9. Juni 2023 · John F. Seymour. First published: 09 June 2023. https://doi.org/10.1002/hon.3146. Sections. PDF. Tools. This section will review the assessment and approved and generally available treatment options for patients with relapsed CLL, including the context of Richter Transformation (the development of diffuse large B-cell lymphoma). 1.

8. pubmed.ncbi.nlm.nih.gov › 32358081Association of early disease progression and very poor ... -...

   pubmed.ncbi.nlm.nih.gov › 32358081

   Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.